P1.08-075 Salvage Surgery for Stage IV Non-Small Cell Lung Cancer
نویسندگان
چکیده
منابع مشابه
Management Issues for Stage IV Non-Small Cell Lung Cancer.
BACKGROUND:The management of stage IV non-small-cell lung cancer (NSCLC) has been a controversial subject over the past several decades. Data from randomized trials and from phase II trials on new cancer agents are changing physician attitudes and treatment practices. METHODS: The literature on the management of metastatic lung cancer was reviewed and interpreted. RESULTS: There is good evidenc...
متن کاملTreatment of Stage IV Non-small Cell Lung Cancer
Background: Stage IV non-small cell lung cancer (NSCLC) is a treatable, but not curable, clinical entity in patients given the diagnosis at a time when their performance status (PS) remains good. Methods: A systematic literature review was performed to update the previous edition of the American College of Chest Physicians Lung Cancer Guidelines. Results: The use of pemetrexed should be restric...
متن کاملChemotherapeutic management of stage IV non-small cell lung cancer.
Stage IV non-small cell lung cancer (NSCLC) denotes the presence of metastatic disease and is largely incurable using present-day therapies. Chemotherapy remains a therapeutic option in this patient population, and there are many pertinent issues surrounding its use in patients with stage IV NSCLC. Eleven questions were framed by the American College of Chest Physicians Lung Cancer Guidelines C...
متن کاملSurgery for non-small cell lung cancer.
BACKGROUND As part of an evaluation of the lung cancer surgery at Akershus University hospital we wanted to describe the lung cancer surgery programme, assess 30-day mortality and review complications. MATERIAL AND METHOD We retrospectively examined medical records of all patients undergoing potentially curative surgery for non-small-cell lung cancer. RESULTS The 99 patients operated on wer...
متن کاملPerspectives on salvage therapy for non-small-cell lung cancer.
Platinum-based chemotherapy offers a modest survival advantage over best supportive care in chemotherapy-naive patients with a good performance status and advanced/metastatic non-small-cell lung cancer (NSCLC). Despite the survival benefit associated with first-line chemotherapy, the majority of patients will experience relapse or disease progression. In clinicalpractice, an increasing number o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2017
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2016.11.1042